Results 11 to 20 of about 27,127 (159)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021

Blood Cancer Journal, 2021
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients ...
M. Hasib Sidiqi, Morie A. Gertz
doaj   +2 more sources

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +2 more sources

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

Nature Communications, 2022
Immunoglobulin light chain amyloidosis is a lethal hematologic disorder driven by clonal plasma cells producing abnormal light chains that damage healthy tissues. Fraser et al.
Cameron S. Fraser, Johan K. E. Spetz, Xingping Qin, Adam Presser, Jonathan Choiniere, Chendi Li, Stacey Yu, Frances Blevins, Aaron N. Hata, Jeffrey W. Miller, Gary A. Bradshaw, Marian Kalocsay, Vaishali Sanchorawala, Shayna Sarosiek, Kristopher A. Sarosiek   +14 more
doaj   +2 more sources

Púrpura: manifestação de amiloidose sistémica primária. [PDF]

Acta Médica Portuguesa, 2009
Primary Systemic Amyloidosis (AL) is the most frequent form of systemic amyloidosis and its morbilility is associated with immunoglobulin light chains deposition in vital organs. The mucocutaneous manifestations occur in about 30-40% of the cases and are
Sara Lestre, Andreia Gonçalves, Alexandre João, Ana Ferreira, Margarida Apetato   +4 more
doaj   +2 more sources

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient

Nature Communications, 2019
Immunoglobulin Light Chain Amyloidosis (AL) is the most common systemic amyloidosis occurring in Western countries. Here the authors present the 4.0 Å cryo-EM structure of light chain AL55 fibrils that were isolated from the heart of an AL systemic ...
Paolo Swuec, Francesca Lavatelli, Masayoshi Tasaki, Cristina Paissoni, Paola Rognoni, Martina Maritan, Francesca Brambilla, Paolo Milani, Pierluigi Mauri, Carlo Camilloni, Giovanni Palladini, Giampaolo Merlini, Stefano Ricagno, Martino Bolognesi   +13 more
doaj   +2 more sources

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

New England Journal of Medicine, 2021
BACKGROUND Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.
E. Kastritis, G. Palladini, M. Minnema, A. Wechalekar, A. Jaccard, Hans C. Lee, V. Sanchorawala, S. Gibbs, P. Mollee, C. Venner, Jin-Hai Lu, S. Schönland, M. Gatt, Kenshi Suzuki, Kihyun Kim, M. Cibeira, M. Beksaç, E. Libby, J. Valent, V. Hungria, S. Wong, M. Rosenzweig, N. Bumma, A. Huart, M. Dimopoulos, D. Bhutani, A. Waxman, S. Goodman, J. Zonder, Selay Lam, K. Song, T. Hansen, S. Manier, W. Roeloffzen, K. Jamroziak, F. Kwok, C. Shimazaki, Jin-Seok Kim, E. Crusoé, T. Ahmadi, N. Tran, X. Qin, S. Vasey, B. Tromp, J. Schecter, B. Weiss, S. Zhuang, J. Vermeulen, G. Merlini, R. Comenzo   +49 more
semanticscholar   +1 more source

Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment

American journal of hematology/oncology, 2022
Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
M. Gertz
semanticscholar   +1 more source

Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.

The Journal of the National Comprehensive Cancer Network, 2023
Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder with multiple clinical presentations. The diagnosis of AL amyloidosis requires a high index of suspicion, making a delay in diagnosis common, which contributes to the high early
S. Zanwar, M. Gertz, Eli Muchtar
semanticscholar   +1 more source

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

Hemato, 2022
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +3 more
doaj   +1 more source

Syndrome in Question [PDF]

Anais Brasileiros de Dermatologia, 2015
Immunoglobulin light chain amyloidosis is the most common acquired systemic amyloidosis. Its presentation is often insidious and progressive, which may delay diagnosis.
Han MA, Meilan Chen, Juan Li, Ying Li, Shu Qiu   +4 more
doaj   +1 more source